Shah Bukhari 2021.

Study characteristics
Methods	Trial design: open‐label RCT with 2 parallel arms Type of publication: preprint Setting: inpatient Recruitment dates: March to June 2020 Country: Pakistan Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: NCT04392713 Date of registration: 19 May 2020
Participants	Number of participants (randomized/analyzed): 100/86 Age (mean): overall 41 (SD NR) years Males, n: overall 73 (85%) Severity of condition according to study definition: hospitalized, mild‐to‐moderate symptoms Severity of condition according to WHO scale: 4 to 5 Co‐morbidities: diabetes, hypertension Virus detection performed at baseline (test‐positive at baseline): RT‐PCR (100%) (relevant population 100% test‐positive) Inclusion criteria: provision of signed and dated informed consent form; stated willingness to comply with all study procedures and admission for the duration of the study; male or female; aged 15–65 years; in good general health with no or mild‐to‐moderate symptoms of COVID‐19; PCR positive for SARS‐CoV‐2; ability to take oral medication Exclusion criteria: SARS‐CoV‐2 infection with severe symptoms, likely due to cytokine release syndrome; uncontrolled co‐morbidities, and immunocompromised states; history of ivermectin allergy; receiving CYP 3A4‐inhibitors or ‐inducers
Interventions	Details of intervention Type and dose: ivermectin 12 mg, single dose Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care including vitamin C, vitamin D3, paracetamol administered in both study arms; unclear whether standard of care included chloroquine as stated in the protocol Duration of follow‐up: 28 days Treatment cross‐overs: none
Outcomes	Primary study outcome Days to achieve RT‐PCR negativity Relevant review outcomes reported Viral clearance (RT‐PCR) at 3, 7, and 14 days Adverse events within 28 days Additional study outcomes reported None
Notes	Date of publication: 5 February 2021 Sponsor/funding: departmental resources Correspondence with the author team: author request sent (publication status, outcome data including number of participants and events for participants with negative RT‐PCR at 7 and 14 days); no response received from the author Information on ethics votum: name of responsible ethics committee, reference number of proposal, and votum reported